Harrow (HROW) Share-based Compensation (2010 - 2026)
Harrow (HROW) posted quarterly Share-based Compensation of $3.8 million for Q1 2026, down 15.78% year-over-year from $4.6 million in Q1 2025, and up 0.97% quarter-over-quarter from $3.8 million in Q4 2025.
Harrow (HROW) Share-based Compensation (2010 - 2026) Analysis & Trends
Harrow's Share-based Compensation history runs 17 years deep, the most recent figure standing at $3.8 million for Q1 2026.
- In Q1 2026, Share-based Compensation fell 15.78% year-over-year to $3.8 million; the TTM figure through Mar 2026 stood at $11.8 million (down 34.57% YoY), while the FY2025 annual figure was $12.5 million, down 29.04% from the prior year.
- Share-based Compensation for Q1 2026 stood at $3.8 million, up from $3.8 million in the prior quarter.
- The five-year high for Share-based Compensation was $5.8 million in Q4 2022, with the low at $875000.0 in Q2 2025.
- The 5-year median for Share-based Compensation is $4.2 million (2024), against an average of $3.6 million.
- The sharpest annual moves came in 2022 and 2025: Share-based Compensation soared 173.57% in 2022, then sank 79.51% in 2025.
- Harrow's Share-based Compensation stood at $5.8 million in 2022, then declined by 27.84% to $4.2 million in 2023, then advanced by 14.83% to $4.8 million in 2024, then slipped by 20.73% to $3.8 million in 2025, then grew by 0.97% to $3.8 million in 2026.
- Business Quant data shows HROW's Share-based Compensation at $3.8 million in Q1 2026, $3.8 million in Q4 2025, and $3.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 40.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 26.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 114.12 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 19.00 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 30.40 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 65.00 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 7.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Harrow | 1.56 Bn | 1.47 Bn | 50.36 Mn | 3.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.79 Mn |
| Jun 30, 2026 | 3.79 Mn |
| Mar 31, 2026 | 3.84 Mn |
| Mar 31, 2026 | 3.84 Mn |
| Dec 31, 2025 | 3.80 Mn |
| Dec 31, 2025 | 3.80 Mn |
| Sep 30, 2025 | 3.27 Mn |
| Sep 30, 2025 | 3.27 Mn |
| Jun 30, 2025 | 875,000.00 |
| Jun 30, 2025 | 875,000.00 |
| Mar 31, 2025 | 4.56 Mn |
| Mar 31, 2025 | 4.56 Mn |
| Dec 31, 2024 | 4.79 Mn |
| Dec 31, 2024 | 4.79 Mn |
| Sep 30, 2024 | 4.39 Mn |
| Sep 30, 2024 | 4.39 Mn |
| Jun 30, 2024 | 4.27 Mn |
| Jun 30, 2024 | 4.27 Mn |
| Mar 31, 2024 | 4.17 Mn |
| Mar 31, 2024 | 4.17 Mn |